Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials.

Jing Huang Shuyuan Xiong Shenglan Ding Qingfeng Cheng Zhiping Liu

Published in: Journal of diabetes research (2020)

This meta-analysis of randomized controlled trials indicates that ertugliflozin is tolerated by T2DM, but the risk of GMIs is noteworthy, especially among females in the high-dose group.

Keyphrases

high dose
systematic review
low dose
stem cell transplantation
stem cells
type diabetes
metabolic syndrome
adipose tissue
mesenchymal stem cells
cell therapy